Immune evasion is linked to histone variation malfunction. Gene therapy could provide tools for targeting histone variant deposition as a critical part of its pharmacology
For a range of cancer-related processes, histone variants play a function. MacroH2A1.1's ADP ribose-binding properties have emerged as a connection between metabolites and the epigenome that must be studied further in vivo. Based on the data we have discovered thus far, we think that altered histone variant functions are co-opted by transformed cells with varying outcomes over the evolutionary trajectory of the tumor. However, our current understanding of histone variations in tumor dormancy and treatment resistance is insufficient. H3 mutations are most common in solid tumors, but they have also been found in hematological malignancies.In addition, a study of over 3,000 patient samples from various cancer types found that all core histones are mutated in 4% of cancers, but the role of these newly formed mutations is unknown.However, an ongoing study is investigating how to better characterize tumor response, as well as how to better predict patient survival in difficult-to-treat cancers. Based on many studies, we hypothesize that altered gene expression levels in tumor cells or tumor-associated cells can change the immunological microenvironment. Histone variation dysfunction influences the genes associated with immune evasion, which in turn affects immune-therapy responsiveness.The success of our goal depends on developing unique, pharmacologically practical ways to target histone variant deposition. Since histone chaperones lack enzymatic capabilities and possess large surfaces without deep pockets where small-molecule inhibitors may act, this has proven problematic thus far. Since cell identity is dependent on histone variants and chaperones, it is reasonable to ponder if cell destiny is lost due to histone variant and chaperone regulation. Histone variants may still be utilized to predict therapeutic response while we wait for these data, helping to personalize treatments and enhancing patient survival and quality of life.